Skip to content

Use of Cannabidiol (CBD) Oil to relieve pain and burning in people with Burning Mouth Syndrome

Evaluation of the analgesic effect of Cannabidiol (CBD) Oil on symptom reduction in patients with Burning Mouth Syndrome: a non-randomized controlled clinical trial -

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-8mqxc4b
Enrollment
Unknown
Registered
2025-07-24
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Mouth Syndrome

Interventions

This is a two-arm, single-blind, randomized controlled clinical trial. The expected sample size is 35 participants in each group, who will be allocated through a computer-generated random sequence. Ex
E02.190.755

Sponsors

Hospital de Clínicas da Universidade Federal do Paraná
Lead Sponsor
Universidade Federal do Paraná
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years of age; both genders; previous diagnosis of Burning Mouth Syndrome; diagnosed during the study

Exclusion criteria

Exclusion criteria: history of Liver Disease; using Anticoagulants; family history of Schizophrenia; symptoms associated with other comorbidities

Design outcomes

Primary

MeasureTime frame
A substantial decrease in the burning mouth sensation is expected during the medication use period, as measured by the visual analog scale for pain intensity, based on the observation of at least a 50% variation between pre- and post-intervention assessments.

Secondary

MeasureTime frame
An improvement in patients' quality of life is expected during the medication use period, as assessed by the OHIP-14 questionnaire, based on the observation of at least a 50% variation between pre- and post-intervention measurements.

Countries

Brazil

Contacts

Public ContactGuilherme Klein Parise

Universidade Federal do Paraná

guiparise@gmail.com+55(41)987030323

Outcome results

None listed

Source: REBEC (via WHO ICTRP)